Over the past two decades, biotechnology innovation has transformed treatment outcomes for many life threatening diseases. Yet access to biological medicines remains profoundly unequal: over 80% of biological medicines are available to less than 15% of the global population, with affordability being the single greatest barrier.

Ena Biologics is addressing this gap through manufacturing innovation - enabling a step-change reduction in the cost of essential biological medicines while maintaining uncompromising quality.

Ena Biologics

Org chart

Teams

Offices

Ena Biologics

Org chart

Teams

Offices

Related companies